A Prospective Multicenter Phase 2 Study of FCR/BR Alternating With Ibrutinib in Treatment-naive Patients With CLL
This is a prospective multicenter phase 2 study designed with the purpose to evaluate the response rate and safety of treatment with FCR/BR alternating with ibrutinib in treatment-naive patients with chronic lymphocytic leukemia.
Chronic Lymphocytic Leukemia
DRUG: FCR and Ibrutinib|DRUG: BR and Ibrutinib|DRUG: Ibrutinib and Thalidomide
CRR, Rate of complete remission, 3 months after completion of induction therapy
ORR, Overall Response Rate, 3 months after completion of induction therapy|OS, Overall survival, 5 years|PFS, Progression-free survival, 5 years|MRD negative rate, the rate of undetectable tumor cells in bone marrow and/or peripheral blood by multicolor flow cytometry, 3 months after completion of induction therapy|DoR, Duration of Response, 5 years|Treatment-related side effects, 10 months
This is a prospective multicenter phase 2 study designed with the purpose to evaluate the response rate and safety of treatment with FCR/BR alternating with ibrutinib in treatment-naive patients with chronic lymphocytic leukemia.